-
公开(公告)号：US10085976B2
公开(公告)日：2018-10-02
申请号：US15212054
申请日：2016-07-15
Inventor： Sang Myun Park , Yu Ree Choi
Abstract: This invention provides a method of treating a neurodegenerative disease selected from the group consisting of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, comprising administering a pharmaceutically effective amount of an agent capable of suppressing expression or activity of SHP-1/-2 (Src homology region 2 domain-containing phosphatase-1/-2) or FcγRIIB (IgG Fc receptor II-B) to a subject having the neurodegenerative disease, wherein the agent capable of suppressing expression of SHP-1/-2 or FcγRIIB is selected from the group consisting of miRNA, siRNA, shRNA, antisense oligonucleotide, and a combination thereof capable of specifically binding to mRNA of SHP-1/-2 or FcγRIIB, and the agent capable of suppressing activity of SHP-1/-2 or FcγRIIB is selected from the group consisting of an antibody, an aptamer, an antagonist, and a combination thereof capable of specifically binding to a protein of SHP-1/-2 or FcγRIIB.
-
公开(公告)号：US12240892B2
公开(公告)日：2025-03-04
申请号：US17113630
申请日：2020-12-07
Inventor： Sang Myun Park , Yu Ree Choi , Jae Bong Kim
IPC: C07K16/18 , A61K39/00 , A61P25/28 , C12N15/113
Abstract: A composition including a substance that inhibits an expression or activity of c-src and its use in inhibiting aggregation and/or migration of α-syn are disclosed. The composition may be a pharmaceutical composition and can be used for preventing or treating synucleinopathy. The substance can inhibit the signal transduction induced by α-syn migrating to adjacent cells, thus mitigating the cytotoxic influence of α-syn on the adjacent cells; and can inhibit the denaturation of monomeric α-syn into aggregated α-syn, which may be a major cause of synucleinopathy, and thus, can be beneficially used as a therapeutic agent for synucleinopathy.
-
公开(公告)号：US20170143686A1
公开(公告)日：2017-05-25
申请号：US15212054
申请日：2016-07-15
Inventor： Yu Ree Choi , Sang Myun Park
IPC: A61K31/47 , G01N33/68 , C12N15/113
CPC classification number: A61K31/47 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12N2310/16 , C12N2310/531 , C12Y301/03048 , G01N33/5058 , G01N33/6854 , G01N33/6896 , G01N2333/70535 , G01N2500/10 , G01N2800/2814 , G01N2800/2835
Abstract: Provided are a pharmaceutical composition for preventing or treating neurodegenerative diseases including an agent capable of suppressing expression or activity of SHP-1/-2 or FcγRIIB, a method of preventing or treating neurodegenerative diseases by administering the pharmaceutical composition, a method of screening for a therapeutic agent for neurodegenerative diseases, a diagnostic composition for neurodegenerative diseases, a diagnostic kit for neurodegenerative diseases including the diagnostic composition, and a method of providing information for the diagnosis of neurodegenerative diseases by using the diagnostic composition or kit.The agent capable of suppressing expression or activity of SHP-1/-2 or FcγRIIB according to the present invention inhibits signal transduction caused by propagation of α-synuclein to neighboring cells, thereby reducing cytotoxicity of α-synuclein to neighboring cells and thus being usefully applied to a therapeutic agent for neurodegenerative diseases. Furthermore, the agent capable of suppressing expression or activity of SHP-1/-2 or FcγRIIB according to the present invention may be an important clue to elucidate the pathogenesis of neurodegenerative diseases, and therefore, contributes to fundamental cure, thereby overcoming neurodegenerative diseases.
-
-
Search Results
3
records
(took 0.015 seconds)
